Sarepta Therapeutics (SRPT) Expected to Release Earnings on Thursday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sarepta Therapeutics to post earnings of $0.0740 per share and revenue of $352.20 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.42. The business had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. Sarepta Therapeutics’s revenue for the quarter was down 34.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 earnings per share. On average, analysts expect Sarepta Therapeutics to post $3.27 EPS for the current fiscal year and $1.34 EPS for the next fiscal year.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $18.54 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The business has a 50-day simple moving average of $19.24 and a two-hundred day simple moving average of $18.69. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -6.39, a PEG ratio of 0.33 and a beta of 0.45. Sarepta Therapeutics has a 52 week low of $14.68 and a 52 week high of $24.68.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Benchmark reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday, September 9th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, July 9th. Zacks Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Royal Bank Of Canada lowered their price target on shares of Sarepta Therapeutics from $19.00 to $17.00 and set a “sector perform” rating on the stock in a report on Thursday, October 8th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $23.40.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.